Rachel A. Foot , MD

Medical Degree: The University of Toledo College of Medicine Toledo, OH,

Bachelor's Degree: University of Michigan Ann Arbor, MI, (Movement Science and Latin Language, Litterature, and Culture minor)

Residency: University of Cincinnati Cincinnati, OH, 2015 (Internal Medicine)

Fellowship: University of Cincinnati Cincinnati, OH, 2015 (Pulmonary)

Fellowship: University of Cincinnati Cincinnati, OH, 2018 (Pulmonary & Critical Care)

American Board of Internal Medicine (Critical Care Medicine) (Certification Date: 11-12-2018 )

American Board of Internal Medicine (Certification Date: 08-12-2015 )

American Board of Internal Medicine (Pulmonary Disease) (Certification Date: 10-19-2017 )

Critical Care Medicine

Lung Disease

Pulmonary Disease

Rare Lung Disease

Sarcoidosis

Asbestosis

Bronchiolitis

Chronic Cough

Dyspnea

Histoplasmosis

Idiopathic Pulmonary Fibrosis

Interstitial Lung Disease (ILD)

Legionnaires' Disease (Legionellosis)

Pleurisy

Pneumonia

Pneumonitis

Pulmonary Fibrosis

Pulmonary Sarcoidosis

Respiration Disorders

Respiratory Syncytial Virus (RSV)

Respiratory Tract Disease

Respiratory Tract Infections

Shortness of Breath

Thoracic Disease

Tuberculosis

Whooping Cough (Pertussis)

Critical Care Medicine

Internal Medicine

Interstitial Lung Disease, Critical Care

 

Grant: #Duke; tba; 10T2HL156812-01; RECOVER-VIAL Investigators:Becker, Richard; Foot, Rachel -06-30-2024 National Heart, Lung and Blood Institute RECOVER-VITAL: A Platform Protocol for Evaluation of Interventions for Viral Persistence, Viral Reactivation, and Immune Dysregulation in Post-Acute Sequelae of SARS-CoV-2 Infection (PASC) Role:Collaborator 0.00 Hold Level:Federal

Investigators:Foot, Rachel 09-29-2023 -09-28-2026 Third Pole Therapeutics A Within subject Device setting Escalation Early Feasibility Study Evaluating the Safety, Tolerability, and Functionality of 3P-100, an Electric Nitric Oxide (NO) Ambulatory Production and Delivery Sy Role:PI 0.00 Hold Level:Industry

Grant: #WBSE: 383000909; SPS: 280176/ 10T2HL156812-01 Investigators:Foot, Rachel -12-31-2024 National Heart, Lung and Blood Institute RECOVER-VITAL: A Platform Protocol for Evaluation of Interventions for Viral Persistence, Viral Reactivation, and Immune Dysregulation in Post-Acute Sequelae of SARS-CoV-2 Infection (PASC) Role:PI 0.00 Hold Level:Federal

Grant: #Duke; WBSE 383001278; SPS 282235; 10T2HL156812-01; RECOVER SLEEP Investigators:Foot, Rachel; Romaker, Ann 09-25-2023 -12-31-2024 National Heart, Lung and Blood Institute RECOVER-SLEEP: A Platform Protocol for Evaluation of Interventions for Sleep Disturbances in Post-Acute Sequelae of SARS-CoV-2 Infection (PASC) Role:Collaborator 55001.47 Hold Level:Federal

Grant: #GSK-218224 Investigators:Foot, Rachel 02-19-2024 -02-19-2027 GlaxoSmithKline PLC (United Kingdom) A Phase 2/3, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of belimumab administered subcutaneously in adults with systemic sclerosis associate Role:PI 179078.05 Hold Level:Industry

Grant: #D3460C00002 Investigators:Foot, Rachel 04-04-2024 -04-04-2028 AstraZeneca Pharmaceuticals LP A Multicenter, Randomized, Parallel-group, Double-blind, Two-arm, Phase III Study to Evaluate the Safety and Efficacy of Anifrolumab Compared with Placebo in Male and Female Participants 18-70 Role:PI 186496.54 Active Level:Industry

Peer Reviewed Publications

Osterburg, Andrew R; Nelson, Rebecca L; Yaniv, Benyamin Z; Foot, Rachel; Donica, Walter R F; Nashu, Madison A; Liu, Huan; Wikenheiser-Brokamp, Kathryn A; Moss, Joel; Gupta, Nishant; McCormack, Francis X; Borchers, Michael T (2016. ) NK cell activating receptor ligand expression in lymphangioleiomyomatosis is associated with lung function decline.JCI insight, , 1 (16 ) ,e87270 More Information

Academic - Internal Medicine
Medical Sciences Building Room 6352D
Cincinnati  Ohio, 45267
Phone: 513-558-4831
rachel.foot@uc.edu